This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Hetrombopag
- DrugBank Accession Number
- DB16184
- Background
Hetrombopag is under investigation in clinical trial NCT03976882 (Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Malignancy.).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Hetrombopag (DB16184)
- Weight
- Average: 458.474
Monoisotopic: 458.159019824 - Chemical Formula
- C25H22N4O5
- Synonyms
- Not Available
- External IDs
- SHR-8735
- SHR8735
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9WGT51BDDL
- CAS number
- 1257792-41-8
- InChI Key
- BDGGFTDRPHKXFC-QYQHSDTDSA-N
- InChI
- InChI=1S/C25H22N4O5/c1-14-22(24(31)29(28-14)17-10-9-15-5-2-3-6-16(15)13-17)27-26-19-8-4-7-18(23(19)30)20-11-12-21(34-20)25(32)33/h4,7-13,26,30H,2-3,5-6H2,1H3,(H,32,33)/b27-22-
- IUPAC Name
- 5-(2-hydroxy-3-{2-[(4Z)-3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}phenyl)furan-2-carboxylic acid
- SMILES
- CC1=NN(C(=O)\C1=N/NC1=C(O)C(=CC=C1)C1=CC=C(O1)C(O)=O)C1=CC=C2CCCCC2=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 52084807
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Other Primary Immune Thrombocytopenia (ITP) 1 3 Active Not Recruiting Treatment Chemotherapy-Induced Thrombocytopenia 1 3 Not Yet Recruiting Treatment Chemotherapy-Induced Thrombocytopenia 1 3 Recruiting Treatment Immune Thrombocytopenia (ITP) 1 2 Not Yet Recruiting Treatment Breast Cancer 1 2 Not Yet Recruiting Treatment Myelodysplastic Syndromes (MDS) 1 2 Recruiting Treatment Hepatic Disease 1 2, 3 Not Yet Recruiting Treatment Aplastic Anemia / Effect of Drugs 1 2, 3 Not Yet Recruiting Treatment Myelodysplastic Syndromes (MDS) 1 1 Completed Basic Science Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0528 mg/mL ALOGPS logP 4.03 ALOGPS logP 5.43 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 3.13 Chemaxon pKa (Strongest Basic) -0.35 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 127.73 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 126.15 m3·mol-1 Chemaxon Polarizability 49.15 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 15, 2020 18:14 / Updated at December 20, 2020 03:38